342899-07-4

Usage

Uses

Used in Organic Synthesis:
(2-Ethyl-4-Methoxyphenyl)boronic acid is used as a reagent in organic synthesis for the formation of carbon-carbon and carbon-heteroatom bonds. Its ability to form stable intermediates makes it a valuable component in the synthesis of complex organic molecules.
Used in the Suzuki Coupling Reaction:
In the field of chemical synthesis, (2-Ethyl-4-Methoxyphenyl)boronic acid is used as a reagent in the Suzuki coupling reaction. This widely used method allows for the efficient construction of complex organic molecules, making it an essential tool for researchers and practitioners in the field.
Used in Pharmaceutical Compound Design:
(2-Ethyl-4-Methoxyphenyl)boronic acid is used as a building block in the design of pharmaceutical compounds. Its potential pharmacological applications have been studied, and it is of interest to researchers and practitioners in drug discovery due to its versatility and usefulness in organic chemistry.
Used in Chemical Research:
Due to its unique properties and applications, (2-Ethyl-4-Methoxyphenyl)boronic acid is used in various research projects to explore new methods and applications in chemical synthesis and drug discovery. Its role in the development of novel compounds and therapeutic agents makes it a valuable resource for the scientific community.

Upstream product

• 34881-44-2 4-bromo-3-ethyl-1-methoxybezene 

Relevant academic research and scientific papers

SUBSTITUTED DIHYDRO AND TETRAHYDRO OXAZOLOPYRIMIDINONES, PREPARATION AND USE THEREOF

The present invention relates to a series of substituted dihydro and tetrahydro oxazolopyrimidinones, specifically, to a series of 2-substituted-2,3-dihydro-oxazolo[3,2-a]pyrimidin-7-ones and 2-substituted-2,3,5,6-tetra-hydro-oxazolo[3,2-a]pyrimidin-7-ones of formula (I): Wherein p, n, X, Y, R1, R2, R3, R4, R5, R6, R7 and R8 are as defined herein. This invention also relates to methods of making these compounds including novel intermediates. The compounds of this invention are modulators of metabotropic glutamate receptors (mGluR), particularly, mGluR2 receptor. Therefore, the compounds of this invention are useful as pharmaceutical agents, especially in the treatment and/or prevention of a variety of central nervous system disorders (CNS), including but not limited to acute and chronic neurodegenerative conditions, psychoses, convulsions, anxiety, depression, migraine, pain, sleep disorders and emesis.

Eleven amino acid glucagon-like peptide-1 receptor agonists with antidiabetic activity

Glucagon-like peptide 1 (GLP-1) is a 30 or 31 amino acid peptide hormone that contributes to the physiological regulation of glucose homeostasis and food intake. Herein, we report the discovery of a novel class of 11 amino acidGLP-1 receptor agonists. These peptides consist of a structurally optimized 9- mer, which is closely related to the N-terminal 9 amino acids ofGLP-1, linked to a substituted C-terminal biphenylalanine (BIP) dipeptide. SAR studies resulted in 11-mer GLP-1R agonists with similar in vitro potency to the native 30-mer. Peptides 21 and 22 acutely reduced plasma glucose excursions and increased plasma insulin concentrations in a mouse model of diabetes. These peptides also showed sustained exposures over several hours in mouse and dog models. The described 11-mer GLP-1 receptor agonists represent a new tool in further understanding GLP-1 receptor pharmacology that may lead to novel antidiabetic agents.

Process for the preparation of amino acids useful in the preparation of peptide receptor modulators

The present invention provides process useful for the preparation of intermediates which are useful in the preparation of amino acids useful in preparing peptide receptor modulators, for example agonists or partial agonists of such peptide receptors. Such